<DOC>
	<DOCNO>NCT00206986</DOCNO>
	<brief_summary>The investigator want try improve information processing schizophrenic patient via pharmacological intervention . The hypothesis decrease noradrenergic activity normalize information processing ( PPI , P50 gating , P300 , mismatch negativity ) patient schizophrenia .</brief_summary>
	<brief_title>Will Decreased Noradrenergic Activity Normalize Information Processing Patients With Schizophrenia ?</brief_title>
	<detailed_description>A number report literature provide evidence , among others , increased central noradrenergic activity schizophrenia . In addition increase noradrenergic activity , patient schizophrenia often show reduced filtering sensory information , reflect reduced P50 suppression reduce prepulse inhibition startle reflex ( PPI ) . In two separate initial study laboratory , find reduce sensory gating follow administration imipramine ( combine noradrenergic serotonergic agonist ) desipramine ( highly specific noradrenergic agonist ) healthy volunteer . This provide evidence direct causal relation increase noradrenergic activity disturb gate sensory information , commonly find patient schizophrenia . Therefore , follow-up study , effect noradrenergic antagonist investigate sensory gating patient schizophrenia . To extend data initial study , patient additionally test two psychophysiological parameter attention usually find disturbed patient schizophrenia , i.e . mismatch negativity selective attention . The design conform double blind , placebo control experiment , either four dos ( 0.25 ug , 50 ug , 75 ug 150 ug ) clonidine placebo add current medical treatment 20 male patient schizophrenia five occasion , separate least week , test Copenhagen Psychophysiological Test Battery ( CPTB ) .In order test effect clonidine healthy volunteer , 20 healthy male receive fix dose 0.15 mg clonidine placebo two separate occasion separate least week , test CPTB well .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Patients : Male subject Meeting DSMIV diagnosis schizophrenia Controls : Male subject Good Physical Mental Health meeting criterion `` never mentally ill '' , evaluate medical history checklist Non smoker Patients : A P50 suppression PPI score fall within range 10 percent mean score healthy control group Controls : Current use medication Any subject receive investigational medication within 30 day prior start study History neurologic illness History psychiatric illness firstdegree relative , evaluate DSMIV criterion History alcohol drug abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Information processing</keyword>
	<keyword>PPI</keyword>
	<keyword>P50 gating</keyword>
	<keyword>P300</keyword>
	<keyword>mismatch negativity</keyword>
	<keyword>clonidine</keyword>
</DOC>